Panbela Therapeutics (Panbela Therapeutics) Float Percentage Of Total Shares Outstanding : 100.10% (As of Jun. 13, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Panbela Therapeutics's float shares is 4.85 Mil. Panbela Therapeutics's total shares outstanding is 4.85 Mil. Panbela Therapeutics's float percentage of total shares outstanding is 100.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Panbela Therapeutics's Insider Ownership is 30.26%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Panbela Therapeutics's Institutional Ownership is 1.67%.

Panbela Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Panbela Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	4.85	/	4.85
	=	100.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panbela Therapeutics (Panbela Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387

Website

https://www.panbela.com

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Executives

Jennifer K. Simpson	director, officer: President and CEO	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath	officer: V.P. of Finance & CFO	4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob	director	712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer	director	712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust	10 percent owner	1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson	10 percent owner	130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel	director	712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill	director	712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen	officer: Chief Financial Officer	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen	director	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr	director
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen	director	712 VISTA BLVD, #305, WACONIA MN 55387